SUPPLEMENTARY APPENDIX

Supplement to: 'Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma'

Content   Page

Table S1. Characteristics of patients who received adjuvant therapy in discovery cohort 2

	N	%
Type of adjuvant therapy		
Anti-PD-1[a]	39	100
Time to start adjuvant therapy (in weeks)		
Median	9.0	
IQR	7.9-11.7	
Range	4.0-23.1[b]	
Treatment ongoing		
No	39	100
Time on adjuvant treatment		
Median	10	
IQR	3-10	
Range	0-12	
Reason stop end of adjuvant therapy		
End of treatment	22	56
Toxicity[c]	6	15
Recurrence	10	26
Other[d]	1	3
COVID break		
No	24	62
Yes[e]	15	39

Characteristics of adjuvant therapy, reported for the 39 patients who received at least 1 dose of adjuvant therapy.

Reported as number (%), percentages may not total 100 due to rounding.

[a] One patient participated in a trial and was randomized between either anti-PD-1 monotherapy, or combination anti-PD-1 and anti-CTLA-4. [b] One patient started with targeted therapy, due to COVID, but switched to anti-PD-1 due to toxicity. [c] One patient was first treated with targeted therapy due to logistic challenges following the COVID-19 pandemic, then proceeded with adjuvant anti-PD-1. [d] One patient skipped two cycles due to COVID break, did not receive last cycle due to abscess in appendectomy scar. [e] COVID break: eight patients completed 10 cycles instead of 12, 1 patient received 11 cycles and 1 patient had a delayed start of treatment.

Table S2. Cox regression analyses

	Crude HR (95% CI)	*P* value	Adjusted HR (95% CI)	*P* value
Age	1.01 (0.99-1.03)	0.513		
Sex	1.46 (0.88-2.44)	0.143		
Mutation status				
BRAF	1.62 (0.39-6.75)	0.505		
NRAS	1.52 (0.35-6.65)	0.578		
cKIT	2.82 (0.25-31.37)	0.398		
No driver mutations	2.16 (0.46-10.19)	0.330		
Unknown	ref			
Type of surgery				
LND	**0.31 (0.21-0.81)**	**0.010**	0.69 (0.34-1.43)	0.325
ITM	0.61 (0.28-1.33)	0.212	0.98 (0.44-2.23)	0.975
LND + ITM	0.59 (0.23-1.50)	0.266	0.81 (0.31-2.09)	0.661
ILP ± LND	ref		ref	
S100b	**2.39 (1.23-4.63)**	**0.010**	**2.64 (1.29-5.38)**	**0.008**
LDH	1.85 (0.66-5.19)	0.243		
Adjuvant therapy	**0.25 (0.14-0.45)**	**<0.001**	**0.25 (0.13-0.48)**	**<0.001**

HR: hazard ratio; CI: confidence interval; LND: lymph node dissection; ITM: in-transit metastasis; ILP: isolated limb perfusion.

3

Table S3. Baseline characteristics of patients of whom RNA sequencing data is available

		Observation cohort 1A		Adjuvant treatment cohort 2A	
		Recurrence N=18	No recurrence N=6	Recurrence N=9	No recurrence N=15
Age					
	Median	71	73	55	61
	Range	55-77	57-82	45-63	54-73
Sex					
	Male	11 (61)	3 (50)	4 (44)	7 (47)
	Female	7 (39)	3 (50)	5 (56)	8 (53)
Site primary					
	Extremities	13 (72)	3 (50)	4 (44)	8 (53)
	Trunk	4 (22)	3 (50)	5 (56)	5 (33)
	Head&neck	0	0	0	1 (7)
	Acral	0	0	0	1 (7)
	Mucosal	1 (6)	0	0	0
	MUP	0	0	0	0
Breslow thickness					
	≤1.0mm	1 (6)	0	0	3 (20)
	1.01-2.0	4 (22)	1 (17)	2 (22)	2 (13)
	2.01-4.0	6 (33)	4 (80)	5 (56)	4 (27)
	>4.0	5 (28)	0	1 (11)	6 (40)
	Unknown	2 (11)	1 (17)	1 (11))	0
Ulceration					
	No	6 (33)	3 (50)	6 (67)	11 (73)
	Yes	7 (39)	2 (33)	1 (11)	3 (20)
	Unknown	5 (2)	1 (17)	2 (22)	1 (7)
Stage (AJCC 8th edition)					
	IIIB	2 (11)	1 (17)	2 (22)	4 (27)
	IIIC	16 (89)	4 (67)	6 (67)	10 (67)
	IIID	0	0	0	1 (7)
	Unknown	0	1 (17)	1 (11)	0
Mutation status					
	BRAF	9 (50)	4 (67)	6 (67)	9 (60)
	NRAS	6 (33)	1 (17)	1 (11)	6 (40)
	cKIT	1 (6)	0	0	0
	No driver mutations	1 (6)	0	2 (22)	0
	Unknown	1 (6)	1 (17)	0	0
Type surgery					
	LND	8 (44)	2 (33)	7 (78)	11 (73)
	ITM	2 (11)	2 (33)	0	3 (20)
	LND + ITM	2 (11)	1 (17)	2 (22)	1 (7)
	ILP ± LND	6 (33)	1 (17)	0	0
Type sample					
	LND	12 (67)	3 (50)	9 (100)	12 (80)
	ITM	6 (33)	3 (50)	0	3 (20)
S100b					
	≤ULN	14 (78)	6 (100)	7 (78)	14 (93)
	>ULN	2 (11)	0	1 (11)	1 (7)
	Unknown	2 (11)	0	1 (11)	0
LDH					
	≤ULN	16 (89)	4 (67)	8 (89)	15 (100)
	>ULN	1 (6)	2 (33)	0	0
	Unknown	1 (6)	0	1 (14)	0

4

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Baseline characteristics of patients of whom RNA sequencing data is available, reported per cohort for patient with and without recurrence.

Reported as number (%), percentages may not total 100 due to rounding.

IQR: interquartile range; MUP: melanoma of unknown primary; LND: lymph node dissection; ITM: in-transit metastasis; ILP: isolated limb perfusion; ULN: upper limit of normal; LDH: lactate dehydrogenase.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Table S4. Correlation IFNγ with clinical parameters in all patients of whom RNA sequencing data is available

	Pearson coefficient	P value	Spearman coefficient	P value
T stage	0.140	0.295	0.154	0.248
Stage (AJCC 8th edition)	0.021	0.871	0.095	0.455
Breslow thickness	-0.182	0.151	-0.063	0.621
Ulceration	-0.042	0.744	-0.020	0.877
S100B surgery	0.169	0.181	-0.031	0.811
S100B adjuvant	0.223	0.307	0.234	0.282
LDH surgery	-0.020	0.875	-0.073	0.568
LDH adjuvant	0.141	0.522	0.176	0.423
Age	-0.021	0.868	-0.009	0.946
Mutation status	-0.035	0.783	0.003	0.979
Type of surgery	-0.111	0.382	-0.125	0.326

Correlation of interferon-gamma (IFNγ) with known prognostic clinical parameters.

LDH: lactate dehydrogenase.

6

Table S5. Baseline characteristics of patients of whom PD-L1 expression data is available

		Observation cohort 1B		Adjuvant treatment cohort 2B	
		Recurrence	No recurrence	Recurrence	No recurrence
		N=21	N=7	N=11	N=17
Age					
	Median	67	75	59	61
	Range	51-74	73-81	55-70	54-71
Sex					
	Male	9 (43)	4 (57)	5 (46)	7 (41)
	Female	12 (57)	3 (43)	6 (55)	10 (59)
Site primary					
	Extremities	14 (67)	3 (43)	4 (36)	7 (41)
	Trunk	5 (24)	4 (57)	7 (64)	9 (53)
	Head&neck	0	0	0	0
	Acral	0	0	0	1 (6)
	Mucosal	1 (5)	0	0	0
	MUP	1 (5)	0	0	0
Breslow thickness					
	≤1.0mm	1 (5)	0	0	3 (18)
	1.01-2.0	5 (24)	2 (29)	1 (9)	4 (24)
	2.01-4.0	10 (48)	3 (43)	5 (6)	4 (24)
	>4.0	3 (14)	1 (14)	3 (27)	6 (35)
	Unknown	2 (10)	1 (14)	2 (18)	0
Ulceration					
	No	7 (33)	2 (29)	5 (45)	10 (59)
	Yes	7 (33)	3 (43)	3 (27)	6 (35)
	Unknown	7 (33)	2 (29)	3 (27)	1 (6)
Stage (AJCC 8th edition)					
	IIIB	1 (5)	0	2 (18)	4 (24)
	IIIC	20 (95)	6 (86)	8 (73)	12 (71)
	IIID	0	0	0	1 (6)
	Unknown	0	1 (14)	1 (9)	0
Mutation status					
	BRAF	12 (57)	3 (43)	8 (73)	11 (65)
	NRAS	5 (24)	0	2 (18)	6 (35)
	cKIT	1 (5)	0	0	0
	No driver mutations	2 (10)	2 (29)	1 (9)	0
	Unknown	1 (5)	2 (29)	0	0
Type surgery					
	LND	8 (38)	2 (29)	8 (73)	12 (71)
	ITM	6 (29)	2 (29)	1 (9)	3 (18)
	LND + ITM	1 (5)	2 (29)	2 (18)	1 (6)
	ILP ± LND	6 (29)	1 (4)	0	1 (6)
Type sample					
	LND	12 (57)	4 (57)	10 (1)	14 (82)
	ITM	9 (43)	3 (43)	1 (9)	3 (18)
S100b					
	≤ULN	15 (71)	6 (86)	9 (82)	16 (94)
	>ULN	4 (19)	0	2 (18)	1 (6)
	Unknown	2 (10)	1 (14)	0	0
LDH					
	≤ULN	15 (71)	4 (57)	10 (91)	17 (100)
	>ULN	3 (14)	2 (29)	0	0
	Unknown	3 (14)	1 (14)	1 (9)	0

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Baseline characteristics of patients of whom PD-L1 expression data is available, reported per cohort for patients with and without recurrence.

Reported as number (%), percentages may not total 100 due to rounding.

IQR: interquartile range; MUP: melanoma of unknown primary; LND: lymph node dissection; ITM: in-transit metastasis; ILP: isolated limb perfusion; ULN: upper limit of normal; LDH: lactate dehydrogenase.

**Figure S1.** Flow diagram of patient selection

RNAseq: RNA sequencing.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Figure S2. Interferon-gamma score

Bar plots with number of patients with an early recurrence with low and high IFNγ score.
IFNγ: interferon-gamma.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Figure S3. Overview of immune subsets of Danaher


*: significant difference (P<0.005); ns: not significant difference. Immune subsets as defined by Danaher et al. Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer 2017.

11

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Figure S4. Overview of immune subsets of the MCP counter



*: significant difference (P<0.005); ns: not significant difference. Immune subsets as defined by Becht et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 2016.

12

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Figure S5. B cell score

Bar plots with number of patients with an early recurrence with low and high B cell score.

Figure S6. CD20 and CD3 staining

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

A. Dot plots percentage CD20$^+$ cells of patients with and without recurrence reported for total sample, tumor and stroma area.

B. Correlation of B cell score based on RNAseq compared to percentage CD20$^+$ cells for the total samples, tumor and stroma area.

C. Correlation of T cell score based on RNAseq compared to percentage CD3$^+$ cells for the total samples, tumor and stroma area.

D. Correlation of B cell score compared to IFNγ score.

RNAseq: RNA sequencing.

Figure S7. PD-L1 staining

A. Bar plots with percentage of patients with recurrence, split for a low and high PD-L1 score.

B. Bar plots with number of patients with an early recurrence with low and high PD-L1 score.

C. Recurrence-free survival for patients with a low versus a high PD-L1 score in the no adjuvant cohort.

D. Recurrence-free survival for patients with a low versus a high PD-L1 score in the adjuvant cohort.

E. Recurrence-free survival for patients with a low versus a high PD-L1 score for both the no adjuvant and adjuvant cohort.